Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751528 | PMC |
| http://dx.doi.org/10.4103/ijp.ijp_433_23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alternative approaches for monitoring and evaluation of lymphatic filariasis following mass drug treatment with ivermectin, diethylcarbamazine and albendazole in East New Britain Province, Papua New Guinea.
PLoS Negl Trop Dis
January 2025
Department of Pathology, Center for Global Health and Disease, Case Western Reserve University, Cleveland, Ohio, United States of America.
Background: WHO recommends two annual rounds of mass drug administration (MDA) with ivermectin, diethylcarbamazine, and albendazole (IDA) for lymphatic filariasis (LF) elimination in treatment naïve areas that are not co-endemic for onchocerciasis such as Papua New Guinea (PNG). Whether two rounds of MDA are necessary or sufficient and the optimal sampling strategies and endpoints for stopping MDA remain undefined.
Methods And Findings: Two cross-sectional studies were conducted at baseline (N = 49 clusters or villages) and 12 months after mass drug administration (MDA) with IDA (N = 47 villages) to assess lymphatic filariasis (LF) by circulating filarial antigenemia (CFA) and microfilariae (Mf).
Onchocerciasis is not a major cause of blindness in two endemic villages in Sierra Leone.
BMC Res Notes
January 2025
Helen Keller International, New York, USA.
Objective: Sierra Leone, a country where onchocerciasis is endemic in 14 of the 16 districts, was the focus of our investigation. Despite 17 rounds of annual ivermectin treatment since 2005, a report circulated by a local politician indicated an increase in cases of suspected onchocerciasis-related vision impairment in two villages (Mangobo and Petifu) in Tonkolili district. In response, the National Neglected Tropical Disease Program conducted a comprehensive investigation.
View Article and Find Full Text PDFSpatiotemporal heterogeneity of Rhipicephalus microplus resistance to chemical acaricides at intra-farm level: A case study using ivermectin.
Med Vet Entomol
December 2024
Instituto de Investigación de la Cadena Láctea (IdICaL) (INTA-CONICET), Instituto Nacional de Tecnología Agropecuaria, INTA E.E.A. Rafaela, Rafaela, Argentina.
The aim of this work was to analyse the spatiotemporal heterogeneity of Rhipicephalus microplus (Canestrini, 1888) (Acari: Ixodidae) resistance to chemical acaricides at intra-farm level under different environmental (favourable and unfavourable areas for tick development) and management (different schemes of acaricides applications) conditions using ivermectin as a model. The in vitro larval immersion test (LIT) was used to determine quantitatively the levels of resistance to ivermectin in the different populations and subpopulations of R. microplus analysed.
View Article and Find Full Text PDFArticle Synopsis
- - Scabies is a neglected tropical disease significantly affecting schoolchildren in Ethiopia, with a pooled prevalence of 14.71%, varying from 12.52% in Oromia to 17.09% in Amhara.
- - Factors contributing to scabies infection include shared clothing, common sleeping arrangements, family history of the disease, and parental literacy levels.
- - The findings highlight the need for national health authorities to address scabies prevention and control in Ethiopian communities, focusing on the identified risk factors.
Costs of primary healthcare presentations and hospital admissions for scabies and related skin infections in Fiji, 2018-2019.
PLOS Glob Public Health
October 2024
School of Population and Global Health, University of Melbourne, Melbourne, Australia.
Article Synopsis
- Scabies and related bacterial skin infections are common in tropical and low-income areas, significantly raising healthcare costs and straining health systems.
- The "Big SHIFT" trial in Fiji analyzed scabies and SSTIs from 2018 to 2019, aiming to estimate the healthcare costs associated with these conditions before a mass drug treatment campaign.
- The study found that healthcare costs for scabies and SSTIs in Fiji totaled approximately $3 million annually, with an estimated cost of $3.3 per person, highlighting the economic impact and the potential benefits of prevention efforts.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!